What is ENACT?

Rapid diagnosis and treatment of infectious disease is critical to both the patient and the broader community. ENACT (Early Notification to Act, Control, and Treat) partners with innovators to develop disruptive technologies that detect, prognosticate outcomes, and enable early intervention following exposures to both natural and man-made infectious threats.


ENACT is focused on three innovation objectives:

  • Technologies integrated into everyday life that non-invasively sense changes in a user’s baseline.
  • Disposable, over-the-counter products that test for pre-symptomatic illness.
  • In-home, platform-based devices that monitor changes in health and are built for long-term use.

Through these three objectives, ENACT upends the traditional doctor-patient paradigm by empowering people to take their health and healthcare into their own hands. By giving people timely indication of when they are infected, the objectives 1) shorten illness duration; 2) reduce illness spread; 3) improve access to medical treatment and care; and 4) reduce costs. While improving outcomes, ENACT also seeks to increase user satisfaction.

Enact Flow Diagram

Millions of people are sick every week in the U.S. and ENACT is addressing this population and trying to reduce this number and associated productivity losses.

2017-2018 impact of Influenza in the US
  • Deaths- 79,000
  • Hospitalizations- 960,000

Source: https://www.cdc.gov/flu/about/burden/index.html

Chronic lower respiratory diseases are the fourth leading cause of death per year

Source: https://www.cdc.gov/flu/about/burden/index.html

Diagnosis Diagram ENACT

Evolution of the ENACT detection and reporting technologies

For more information, please contact us at ENACT@hhs.gov

DRIVe (Division of Research, Innovation, and Ventures) was established by the Biomedical Advanced Research and Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR), within the United States Department of Health and Human Services (HHS).